Congressman Marino to Hold Hearing on Drug Competition and Pricing with FDA Commissioner Gottlieb
Washington, D.C.—Tomorrow at 1:00 p.m. Congressman Tom Marino (PA-10) will hold a hearing on anticompetitive behavior and the health care marketplace. The hearing in the House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law, of which Marino is the Chairman, is titled “Antitrust Concerns and the FDA Approval Process.” Two panels of witnesses will testify on competition issues for the pharmaceutical industry and how these anticompetitive practices have harmful effects on patients.
Chairman Marino issued the following statement:
“I am very pleased to be holding this hearing and am eager to hear from the distinguished witnesses regarding the issues around drug competition. I am particularly interested in hearing testimony from Dr. Scott Gottlieb, the Commissioner of the FDA, as he has made drug pricing and competition in the pharmaceutical marketplace a cornerstone early in his tenure.”
"I constantly hear from my constituents about how the pharmaceutical drug market is unfair and prices are too high. This is why earlier this year Ranking Member Cicilline and I introduced H.R. 2212, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act to address anticompetitive concerns associated with the FDA’s Risk Evaluation and Mitigation Strategy, or REMS Program. The CREATES Act addresses an issue that Commissioner Gottlieb has identified himself, that pharmaceutical companies are blocking more affordable generic alternatives from coming to the market. I hope to hear more from Commissioner Gottlieb, and the rest of the witnesses, on the abuses that are involved in the REMS Program and other ways patients lose on account of these and other anticompetitive practices.”